IMAJ | volume 26
Journal 3, March 2024
pages: 162-168
1 Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel
2 Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel
3 Department of Cardiology, Rambam Health Care Campus, Haifa, Israel
Summary
Background:
Patients with inflammatory bowel disease (IBD) are at increased risk after percutaneous coronary intervention (PCI).
Objectives:
To compare the clinical outcomes within 30 days, one year, and five years of undergoing PCI.
Methods:
We conducted a retrospective cohort study of adult patients with IBD who underwent PCI in a tertiary care center from January 2009 to December 2019.
Results:
We included 44 patients, 26 with Crohn’s disease (CD) and 18 with ulcerative colitis (UC), who underwent PCI. Patients with CD underwent PCI at a younger age compared to UC (57.8 vs. 68.9 years,
P < 0.001) and were more likely to be male (88.46% of CD vs. 61.1% of UC,
P < 0.03). CD patients had a higher rate of non-steroidal treatment compared to UC patients (50% vs. 5.56%,
P < 0.001). Acute coronary syndromes (ACS) and/or the need for revascularization (e.g., PCI) were the most common clinical events to occur following PCI, in both groups. Of patients who experienced ACS and/or unplanned revascularization within 5 years, 25% of UC vs. 40% of CD had target lesion failure (TLF) due to in-stent restenosis and 10% of CD had TLF due to stent thrombosis.
Conclusions:
We observed higher rates of TLF in IBD patients compared to the general population as well as differences in clinical outcomes between UC and CD patients. A better understanding of the prognostic factors and pathophysiology of these differences may have clinical importance in tailoring the appropriate treatment or type of revascularization for this high-risk group.